nyuuzyou/wikis huggingface dataset:
Neuroendocrine carcinoma

Back to Top
Note: these are regimens tested in histology-specific populations, please see the main NET page for other regimens.
Last updated on 2024-07-23:2 regimens on this page
2 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Neuroendocrine and Adrenal Tumors.
=Advanced disease, all lines of therapy=
==Cisplatin & Etoposide (EP)==
EP: Etoposide and Platinol (Cisplatin)
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy
Morizane et al. 2022 (TOPIC-NEC)	2014-08-08 to 2020-03-06	Phase 3 (E-switch-ic)	IP 	Did not meet primary endpoint of OS
====Chemotherapy====
*Cisplatin (Platinol) 80 mg/m2 IV once on day 1
*Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 3
21-day cycles
===References===
#TOPIC-NEC: Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC UMIN000014795
==Cisplatin & Irinotecan (IC)==
IP: Irinotecan, Platinol (Cisplatin)
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy
Morizane et al. 2022 (TOPIC-NEC)	2014-08-08 to 2020-03-06	Phase 3 (E-switch-ic)	EP 	Did not meet primary endpoint of OS
====Chemotherapy====
*Cisplatin (Platinol) 60 mg/m2 IV once on day 1
*Irinotecan (Camptosar) 60 mg/m2 IV once per day on days 1, 8, 15
28-day cycles
===References===
#TOPIC-NEC: Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC UMIN000014795
Category:Neuroendocrine carcinoma regimens
Category:Disease-specific pages
Category:Neuroendocrine tumors
Neutropenia & leukopenia

=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ASCO==
*2023: Lehrnbecher et al. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update EuroPMC
**2017: Lehrnbecher et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update EuroPMC
**2012: Lehrnbecher et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation EuroPMC
==NCCN==
*2004: Freifeld et al. Fever and neutropenia clinical practice guidelines. EuroPMC
=Definition=
*Mild neutropenia: ANC (absolute neutrophil count) 1000 to 1500 cells/uL
*Moderate neutropenia: ANC 500 to <1000 cells/uL
*Severe neutropenia: ANC <500 cells/uL
=Evaluation=
May consist of:
*CBC with differential
*Basic metabolic panel (BMP)
*Reticulocyte count
*Vitamin B12 
*Folic acid
*Copper
*Urinalysis
*LDH
*Uric acid
*C3, C4
*ANA, anti-DNA antibody
*Peripheral blood flow cytometry
*Peripheral smear
*Clinical/infection history, autoimmune/rheumatologic disease, lifestyle factors (e.g. alcohol)
*Medications
*Check for splenomegaly and lymphadenopathy
*Bone marrow biopsy
Category:Hematology reference pages
Category:Supportive oncology
New York Presbyterian Hospital (Columbia Campus) Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The Division of Hematology/Oncology in the Department of Medicine at Columbia prepares its fellows to be creative and productive contributors as researchers and clinicians. Our program provides a broad-based clinical training and rigorous development of a research project with opportunities to work with world-class investigators in an outstanding Ivy League University."
==Basic information==
Name: New York Presbyterian Hospital (Columbia Campus) Hematology Oncology Fellowship
Fellowship program website: https://cancer.columbia.edu/hematologyoncology/hematologyoncology-fellowships
ACGME ID: 1553511052
===Leadership===
*Program Director: (not listed)
===Fellowship Coordinator===
Anthony Rainone
Phone: (212) 305-8923
Fax: (212) 305-3035
Email: ar3484@cumc.columbia.edu
==Application process and requirements==
https://cancer.columbia.edu/hematologyoncology/applicants-information
===Process===
*Applications accepted starting in: July
*Application deadline: 
*Applications submitted through ERAS
===Requirements===
*U.S. Citizens, U.S. Permanent Residents, or J-1 visa. "NewYork-Presbyterian Hospital will not petition or sponsor H visas." 
*Completed common application form (CAF)
*Curriculum Vitae
*Personal goals statement
*Medical school transcripts
*2 to 4 letters of reference (from within 1 year of current training). Mandatory letters required from Chief of Service/Department Chair and current Program Director. 
*USMLE and/or COMLEX transcript with scores
*Color photo
*Foreign medical graduates only: ECFMG status report 
==Statistics==
*Number of fellowship positions available per year: 
*Board certification eligibility upon fellowship completion: (depending on what fellow chooses) Hematology and Oncology, Hematology, or Oncology
*Length of fellowship: 3 years
==Schedule==
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*Columbia University Medical Center
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Nilutamide (Nilandron)

==General information==
Class/mechanism: Antiandrogen, nonsteroidal. Nilutamide competitively inhibits the effects of testosterone by interacting with the androgen receptor.Nilutamide (Nilandron) package insertNilutamide (Nilandron) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is used==
*Prostate cancer
==Patient drug information==
*Nilutamide (Nilandron) patient drug information (Chemocare)Nilutamide (Nilandron) patient drug information (Chemocare)
*Nilutamide (Nilandron) patient drug information (UpToDate)Nilutamide (Nilandron) patient drug information (UpToDate)
==History of changes in FDA indication==
*1996-09-19: Initial approval in combination with surgical castration for the treatment of stage D2 metastatic carcinoma of the prostate. (Based on International Anandron Study)
==History of changes in EMA indication==
*1986-07-02: EURD
==Also known as==
*Brand names: Anandron, Nilandron, Zandron
==References==
Category:Drugs
Category:Oral medications
Category:First-generation nonsteroidal antiandrogens
Category:Prostate cancer medications
Category:FDA approved in 1996
Category:EMA approved in 1986
Nimotuzumab (Theraloc)

==General information==
Class/mechanism from the NCI Drug Dictionary: A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Head and neck cancer
*Nasopharyngeal carcinoma
*Pancreatic cancer
==History of changes in NMPA indication==
*2008-01-07: Initial approval in combination with RT for a treatment of nasopharyngeal carcinoma.
==Also known as==
*Code name: hR3
*Brand name: Theraloc
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-EGFR antibodies
Category:Head and neck cancer medications
Category:Nasopharyngeal carcinoma medications
Category:Pancreatic cancer medications
Category:NMPA approved in 2008
Nimustine (ACNU)

==General information==
Class/mechanism: Nitrosourea, alkylates DNA and RNA and may inhibit certain key enzymatic reactions by carbamoylation of amino acids in proteins.
Route: IV
Extravasation: n/a
==Diseases for which it was used==
*Anaplastic glioma
*Glioblastoma
==Also known as==
*Generic names: ACNU, pimustine
*Brand name: Nidran
Category:Drugs
Category:Intravenous medications
Category:Nitrosoureas
Category:Anaplastic glioma medications
Category:Glioblastoma medications
Nintedanib (Vargatef)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3).Nintedanib (Vargatef) package insert Nintedanib (Vargatef) package insert (locally hosted backup)Vargatef manufacturer's website
==Diseases for which it is established==
*Non-small cell lung cancer, nonsquamous
==Diseases for which it is used==
*Non-small cell lung cancer
*Ovarian cancer
==Patient drug information==
*Nintedanib (Vargatef) package insertNintedanib (Vargatef) package insert
*Nintedanib (Vargatef) patient drug information (UpToDate)Nintedanib (Vargatef) patient drug information (UpToDate)
==History of changes in EMA indication==
*2014-11-21: Initial marketing authorization as Vargatef. Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy. (Based on LUME-Lung 1)
==Also known as==
*Code name: BIBF-1120
*Brand names: Cyendiv, Idofnib, Nifev, Nindanib, Nintena, Nintenib, Nintib, Ofev, Vargatef
==References==
Category:Drugs
Category:Oral medications
Category:VEGFR inhibitors
Category:FGFR inhibitors
Category:PDGFR inhibitors
Category:SRC inhibitors
Category:Non-small cell lung cancer medications
Category:Non-small cell lung cancer, nonsquamous medications
Category:Ovarian cancer medications
Category:EMA approved in 2014
Niraparib and abiraterone (Akeega)

==Mechanism of action==
A fixed dose combination of niraparib and abiraterone. Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes PARP-1 and PARP-2, which are involved in DNA repair. Inhibiting PARP-1 and PARP-2 may result in formation of PARP-DNA complexes, DNA damage, apoptosis, and cell death. PARP proteins utilize base-excision repair (BER) to identify and repair single strand DNA breaks. Abiraterone is an antiandrogen, androgen biosynthesis inhibitor, CYP17 inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.
==Diseases for which it is established==
*Prostate cancer, BRCA-mutated
==History of changes in FDA indication==
*2023-08-11: Initial approval with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved test. (Based on MAGNITUDE)
==History of changes in EMA indication==
*2023-04-19: Initial authorisation for treatment of adult patients with prostate cancer.
==Also known as==
*Code name: CJNJ-67652000
*Brand name: Akeega
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:PARP1 inhibitors
Category:PARP2 inhibitors
Category:CYP17 inhibitors
Category:Prostate cancer medications
Category:EMA approved in 2023
Category:FDA approved in 2023
Nirogacestat (Ogsiveo)

==Mechanism of action==
From the NCI Drug Dictionary: A selective gamma secretase (GS) inhibitor with potential antitumor activity. Nirogacestat binds to GS, blocking proteolytic activation of Notch receptors; Notch signaling pathway inhibition may follow, which may result in the induction of apoptosis in tumor cells that overexpress Notch.
==Diseases for which it is used==
*Desmoid tumor
==History of changes in FDA indication==
*2023-11-27: Approved for adult patients with progressing desmoid tumors who require systemic treatment. (Based on DeFi)
==Also known as==
*Code name: PF-03084014
*Brand name: Ogsiveo
Category:Drugs
Category:Oral medications
Category:Gamma secretase inhibitor
Category:Desmoid tumor medications
Category:FDA approved in 2023
Nivolumab and hyaluronidase (Opdivo Qvantig)

==General information==
Class/mechanism: PD-1 receptor antibody. Nivolumab is an IgG4 kappa human monoclonal antibody which binds to the PD-1 (programmed death receptor-1) receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Normally, PD-L1 and PD-L2 binding to the PD-1 receptor on T cells inhibits T-cell proliferation and cytokine production, which can impede immune system surveillance of tumors. By interfering with the binding of PD-L1 and PD-L2 to the PD-1 receptor, nivolumab can cause upregulation of the anti-tumor immune response.
Route: SC
==Toxicity management==
*Immunotherapy toxicity management
==History of changes in FDA indication==
*2024-12-27: Initial approval across approved adult, solid tumor nivolumab indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. (Based on CheckMate 67T [NCT04810078])
==Also known as==
*Generic name: nivolumab and hyaluronidase-nvhy
*Brand name: Opdivo Qvantig
Category:Drugs
Category:Subcutaneous medications
Category:Anti-PD-1 antibodies
Category:FDA approved in 2024
Category:Bristol-Myers Squibb product
Category:Stub
Nivolumab and relatlimab (Opdualag)

==Mechanism of action==
From the NCI Drug Dictionary (for relatlimab): A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth.
==Toxicity management==
*Immunotherapy toxicity management
==Diseases for which it is used==
*Melanoma
==History of changes in FDA indication==
*2022-03-18: Approved for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. (Based on RELATIVITY-047)
==History of changes in EMA indication==
*2022-09-15: initial authorization for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD L1 expression < 1%.
==Also known as==
*Code name: BMS-986016
*Generic name: nivolumab and relatlimab-rmbw
*Brand name: Opdualag
Category:Drugs
Category:Intravenous medications
Category:Anti-PD-1 antibodies
Category:Anti-LAG-3 antibodies
Category:Melanoma medications
Category:Combination drugs
Category:EMA approved in 2022
Category:FDA approved in 2022
Nogapendekin alfa inbakicept (Anktiva)

==Mechanism of action==
From the NCI Drug Dictionary: A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity. Upon administration, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex N-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T cells. The memory T cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation.
==Disease for which it is used==
*Bladder cancer
==History of changes in FDA indication==
*2024-04-22: Approved with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. (Based on QUILT-3.032)
==Also known as==
*Code name: ALT-803, N-803
*Generic name: nogapendekin alfa inbakicept-pmln
*Brand name: Anktiva
Category:Drugs
Category:Bladder cancer medications
Category:Intravesical medications
Category:FDA approved in 2024
Category:Stub
Non-Hodgkin lymphoma

Please click on the links below to access chemotherapy regimens for the following subtypes of lymphoma:
*AIDS/HIV-associated lymphoma
*Aggressive non-Hodgkin lymphoma (diffuse large B-cell lymphoma)
*Burkitt lymphoma
*CNS lymphoma
*Cutaneous B-cell lymphoma
*Cutaneous T-cell lymphoma
*Follicular lymphoma
*Lymphoblastic lymphoma
*Mantle cell lymphoma
*Marginal zone lymphoma
*NK- and T-cell lymphoma
*Post-transplant lymphoproliferative disorder
*Adult T-cell leukemia-lymphoma
Category:Obsolete pages
Non-pegylated liposomal doxorubicin (Myocet)

==General information==
Class/mechanism: A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity.
==Diseases for which it is used==
*Breast cancer
==History of changes in EMA indication==
*2000-07-13: Initial marketing authorization as Myocet.
*Uncertain date: Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.
==Also known as==
*Generic names: liposome-encapsulated doxorubicin citrate, NPLD
*Brand name: Myocet
==References==
Category:Drugs
Category:Intravenous medications
Category:Liposomal chemotherapy
Category:Anthracyclines
Category:Topoisomerase II inhibitors
Category:Breast cancer medications
Category:EMA approved in 2000
Category:Health Canada approved drugs
Non-small cell lung cancer, NRG1-positive

Back to Top
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
There are several related dedicated pages:
*Histology-specific:
**NSCLC, Nonsquamous
**NSCLC, Squamous
*Site-specific:
**NSCLC, CNS metastases
Last updated on 2024-12-22:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ASCO==
*2022: Singh et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline EuroPMC
==ESMO==
*2024: Lee et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer EuroPMC
*2023: Hendriks et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up EuroPMC
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Non-Small Cell Lung Cancer.
=Advanced or metastatic disease, subsequent lines of therapy=
==Zenocutuzumab monotherapy==
===Regimen===
FDA-recommended dose
Study 	Dates of enrollment 	Evidence
Schram et al. 2025 (eNRGy)	2019-09-25 to ongoing	Phase 1/2 (RT)
====Biomarker eligibility criteria====
*NRG1 fusion positive
====Targeted therapy====
*Zenocutuzumab (Bizengri) 750 mg IV over 2 hours once on day 1
14-day cycles
===References===
#eNRGy: Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A; eNRGy Investigators. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. N Engl J Med. 2025 Feb;392(6):566-576. link to original article dosing details in manuscript have been reviewed by our editors link to EuroPMC NCT02912949
Category:Non-small cell lung cancer regimens
Category:Biomarker-specific pages
Category:Non-small cell lung cancers